hyoscine hydrobromide

CLINICAL USE

Motion sickness Premedication Palliative care

DOSE IN NORMAL RENAL FUNCTION

Motion sickness: Oral: 300 mcg 30 minutes before start —of journey then 300 mcg every 6 hours if required; maximum 3 doses in 24 hoursTopical: 1 patch 5–6 hours before —journey, replace after 72 hoursPremedication (SC/IM): 200–600 mcg 30–60 minutes before anaesthesiaSC Infusions: Excessive secretions (patch can also be used for this indication): 0.6–2.4 mg over 24 hoursBowel colic: 20–60 mg over 24 hours

PHARMACOKINETICS

  • Molecular weight                           :438.3
  • %Protein binding                           :10
  • %Excreted unchanged in urine     : 2 (1 – oral, 34 – transdermal)
  • Volume of distribution (L/kg)       :No data
  • half-life – normal/ESRD (hrs)      :8

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Dialysed. Dose as in normal renal function
  • HD                     :Dialysed. Dose as in normal renal function
  • HDF/high flux   :Dialysed. Dose as in normal renal function
  • CAV/VVHD      :Not Dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs

  • None known

    ADMINISTRATION

    Reconstition

    Route

    Oral, topical, SC, IM

    Rate of Administration

    Comments

    OTHER INFORMATION

    Only 2–8% of oral dose is absorbed

  • Related News